¼­¿ï¼º¸ðº´¿ø ¼Ûº´ÁÖ ±³¼ö-À¯¹æ¾Ï ºñ¼ö¼úÀû Ä¡·áÀÇ ÃÖ½ÅÁö°ß
2011/09/26 18:42 ÀÔ·Â
Æ®À§ÅÍ·Î ±â»çÀü¼Û ÆäÀ̽ººÏÀ¸·Î ±â»çÀü¼Û
¡ã °¡Å縯 ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç/¼­¿ï¼º¸ðº´¿ø À¯¹æ¾Ï¼¾ÅÍ/¼Ûº´ÁÖ ±³¼ö

À¯¹æ¾ÏÀº ¼ö¼ú ÈÄ Ã¹ 2~3³â »çÀÌ¿¡ Àç¹ßÀ²ÀÌ °¡Àå ³ôÀº ½Ã±âÀÌ´Ù.(1,2) ¼ö¼ú ÈÄ Àç¹ßÀ» ÁÙÀ̱â À§ÇØ Àü½ÅÀûÀÎ Ä¡·á¿Í ±¹¼ÒÀç¹ß ¹æÁö¸¦ À§ÇÑ Ä¡·á°¡ ÀÌ·ç¾îÁ®¾ß ÇÑ´Ù. ¼ö¼ú ÈÄ Àü½ÅÀûÀÎ Ä¡·á·Î´Â Ç×¾ÏÈ­Çпä¹ý°ú Ç׾ϳ»ºÐºñ¿ä¹ýÀÌ ÀÖÀ¸¸ç, ±¹¼ÒÄ¡·á¿¡´Â ¹æ»ç¼±Ä¡·á°¡ ÀÖ´Ù.

1. Ç×¾ÏÈ­Çпä¹ý

Ç×¾ÏÈ­Çпä¹ýÀ̶õ Ç×¾ÏÁ¦¸¦ ÀÌ¿ëÇÏ¿© ¾Ï¼¼Æ÷¸¦ Á×ÀÌ´Â Ä¡·áÀ̸ç, Ç×¾ÏÁ¦¸¦ Áֻ糪 °æ±¸Åõ¿©ÇÏ¿© Ç×¾ÏÁ¦°¡ Ç÷·ù¸¦ µû¶ó Àü½Å¿¡ ÆÛÁö°Ô ÇÏ¿© ±¹¼ÒÀûÀÎ È¿°ú¿Í ÇÔ²² Àü½Å¿¡ ÆÛÁ®ÀÖ´Â ¹Ì¼¼ÀüÀÌ ¾Ï¼¼Æ÷¿¡ ÀÛ¿ëÇϵµ·Ï ÇÏ´Â Ä¡·áÀÌ´Ù.
Åõ¿©½Ã±â¿¡ µû¶ó ±¸ºÐÇϴµ¥, ù° À¯µµÇ×¾ÏÈ­Çпä¹ýÀº ¿Ü°úÀû ¼ö¼úÀ̳ª ¹æ»ç¼± Ä¡·á¿¡ ¾Õ¼­ ½ÃÇàµÇ¸ç, µÑ° º¸Á¶Ç×¾ÏÈ­Çпä¹ýÀº ¿Ü°úÀû ¼ö¼úÀ̳ª ¹æ»ç¼± Ä¡·á ÈÄ ³²¾ÆÀÖÀ» ¼ö ÀÖ´Â ¾Ï¼¼Æ÷¸¦ Á¦°ÅÇϱâ À§ÇØ ½ÃÇàµÇ°Å³ª, ¹æ»ç¼± Ä¡·á µî ´Ù¸¥ Ä¡·áÀÇ È¿°ú¸¦ »ó½Â½ÃÅ°±â À§ÇØ ½ÃÇàÇÑ´Ù.
Ç×¾ÏÈ­Çпä¹ýÀº ÇÑ°¡Áö Ç×¾ÏÁ¦¸¦ »ç¿ëÇϱ⠺¸´Ù´Â Ä¡·áÈ¿°ú¸¦ »ó½Â½ÃÅ°±â À§ÇØ, ±³Â÷³»¼º(cross-resistance)ÀÌ ¾ø°í, ÀÛ¿ë±âÀüÀÌ ¼­·Î ´Ù¸¥ ¸î °¡Áö ¾àÁ¦¸¦ ÇÔ²² º´¿ëÇÑ´Ù. ÀϹÝÀûÀ¸·Î º´¿ëÅõ¿©°¡ È¿°úÀûÀ̹ǷΠ´ëºÎºÐÀÇ Ç׾Ͽä¹ýÀº º´¿ëÅõ¿©¸¦ ¿øÄ¢À¸·Î ÇÑ´Ù.(3)
Ä¡·á±â°£À̳ª ¹æ¹ýÀº ¼±ÅõǴ ¾àÁ¦¿¡ µû¶ó Â÷À̸¦ º¸ÀÌÁö¸¸, Ä¡·á ½ÃÀÛÀº ¼ö¼ú ÈÄ 8ÁÖ¿¡¼­ 12ÁÖÁÖ»çÀÌ¿¡ ½ÃÀÛÇÏ´Â °ÍÀÌ ÀûÀýÇÏ´Ù.(4) ÁÖÀÇÇÒ Á¡Àº Ä¡·á½Ã±â¸¦ ³õÄ¡°Å³ª Áß´ÜÇϸé È¿°ú°¡ °¨¼ÒÇÒ ¼öµµ ÀÖÀ¸¹Ç·Î ÀÏ´Ü Ä¡·á°¡ ½ÃÀÛµÇ¸é ³¡±îÁö ¸¶Ä¥ ¼ö ÀÖµµ·Ï ÇØ¾ß ÇÑ´Ù.
Ç×¾ÏÁ¦ Åõ¿© ¿ë·®Àº üǥ¸éÀû(¸ö¹«°Ô¿Í Å°¸¦ ÅëÇØ È¯»êÇÑ ¼öÄ¡)À» ±âÁØÀ¸·Î Á¤Çϸç ȯÀÚ¿¡°Ô °¡Àå ÀûÀýÇϸ鼭µµ ¾ÈÀüÇÑ ¿ë·®À» Åõ¿©ÇÑ´Ù. Ç×¾ÏÁ¦ÀÇ °ñ¼ö¾ïÁ¦Á¤µµ´Â Ç÷¾×°Ë»ç¼öÄ¡¸¦ ÅëÇØ ¾Ë ¼ö ÀÖÀ¸¸ç À̸¦ ±âÁØÀ¸·Î Ç×¾ÏÁ¦¿ë·®À» Á¶ÀýÇϱ⵵ ÇÑ´Ù. ÀÌ¿Ü¿¡µµ ºÎÀÛ¿ëÀÇ Á¾·ù¿¡ µû¶ó ³Ê¹« ½ÉÇÑ ºÎÀÛ¿ëÀÌ ³ªÅ¸³ª°Å³ª À§ÇèÀ» ÃÊ·¡ÇÒ ¼öµµ ÀÖ´Ù°í ÆÇ´ÜµÇ¸é ¿ë·®À» ÁÙÀÏ ¼ö ÀÖ´Ù. À¯¹æ¾ÏÀÇ °æ¿ì´Â ´ëºÎºÐÀÇ Ç×¾ÏÁ¦ Åõ¿©´Â ¿Ü·¡¿¡¼­ ÀÌ·ïÁö¸ç ¾àÁ¦ ¹× »óȲ¿¡ µû¶ó ÀÔ¿øÀ» ÇÏ´Â °æ¿ì´Â ¸¹Áö ¾Ê´Ù.
Ç×¾ÏÁ¦´Â ¾Ï¼¼Æ÷¸¦ Á×°Ô ÇÏÁö¸¸, ¾Ï¼¼Æ÷»Ó¸¸ ¾Æ´Ï¶ó ¸ð³¶¼¼Æ÷, °ñ¼ö¼¼Æ÷°°ÀÌ ºü¸¥ Áõ½ÄÀ» ÇÏ´Â ¼¼Æ÷µé¿¡µµ ÀÛ¿ëÇÑ´Ù. Ç×¾ÏÁ¦°¡ °ñ¼ö¼¼Æ÷¿¡ ÀÛ¿ëÇÏ¿© Ç÷¾×¼¼Æ÷ÀÇ »ý»êÀÌ ÁÙ¾îµé¸é ü³» ¸é¿ª»óÅÂÀÇ ÀúÇÏ°¡ ¿À¹Ç·Î ÀÌ·¯ÇÑ »óŸ¦ ÇÇÇϱâ À§ÇØ Ç×¾ÏÁ¦¸¦ ÀûÀýÇÑ °£°ÝÀ» µÎ°í Åõ¿©ÇØ¾ß ÇÑ´Ù. ´ëºÎºÐ Ç×¾ÏÁ¦ÀÇ Åõ¿©°£°ÝÀº 3ÁÖ °£°ÝÀ¸·Î ÇÏ´Â °ÍÀÌ ÀûÀýÇÏ´Ù. ¶ÇÇÑ Ç×¾ÏÁ¦ÀÇ Åõ¿© Ƚ¼ö´Â 4ȸ¿¡¼­ 8ȸ°¡ ÀûÀýÇÏ°í È¿°úÀûÀÎ °ÍÀ¸·Î º¸°í ÀÖ´Ù.
Ç×¾ÏÁ¦¸¦ ¼±ÅÃÀº Ç×¾ÏÁ¦ÀÇ Æ¯¼º¿¡ µû¶ó ȯÀÚ¿¡°Ô °¡Àå ÀûÀýÇÑ ¾àÁ¦¸¦ ¼±ÅÃÇÏ°Ô µË´Ï´Ù. ¸¹Àº Á¾·ùÀÇ Ç×¾ÏÁ¦°¡ ÀÖÀ¸³ª °¢°¢ÀÇ Á¾·ù¿¡ µû¶ó 2-3°¡Áö¸¦ ¼±ÅÃÇÏ¿© º´¿ë Åõ¿©¸¦ ÇÑ´Ù.(5)
À¯¹æ¾ÏȯÀÚ¿¡°Ô º¸Á¶Ç׾Ͽä¹ýÀ¸·Î ÁÖ·Î »ç¿ëÇÏ´Â Ç×¾ÏÁ¦·Î cyclophosphamide, methotrexate, 5-fluorouracil, adriamycin, epirubicinÀÌ º´¿ëÅõ¿©µÇ°í ÀÖ´Ù.(6,7) ƯÈ÷ ÃÖ±Ù¿¡´Â ÀüÀ̼º ȤÀº Àç¹ß¼º À¯¹æ¾Ï¿¡ »ç¿ëµÇ´ø paclitaxel, docetaxelÀ» ¼ö¼ú ÈÄ º¸Á¶ ¿ä¹ýÀ¸·Î ÃʱâºÎÅÍ »ç¿ëÇÏ´Â ¹æ¹ýµµ ÀÖ´Ù.(8,9)
ÀÌ ¿Ü¿¡µµ Ç¥ÀûÄ¡·áÁ¦ÀÎ TrastuzumabÀ» ¼ö¼ú ÈÄ º¸Á¶¿ä¹ýÀ¸·Î »ç¿ëÇϴµ¥, À̸¦ »ç¿ëÇϱâ À§Çؼ­´Â HER-2°¡ °ú¹ßÇöµÈ °æ¿ìÀ̸ç, Á¾¾çÀÇ Å©±â°¡ 1cmÀÌ»óÀ̾î¾ß ÇÑ´Ù.(10)

2. Ç׾ϳ»ºÐºñ¿ä¹ý

³­¼Ò¿¡¼­ ºÐºñµÇ´Â ¿©¼º È£¸£¸óÀÎ ¿¡½ºÆ®·Î°ÕÀº À¯¹æÀÌ Á¤»óÀûÀ¸·Î ¹ßÀ°ÇÏ°í ¹ß´ÞÇÏ´Â °úÁ¤¿¡¼­ ÇʼöÀûÀÌÁö¸¸, ¶ÇÇÑ À¯¹æ¾ÏÀÇ ¹ß»ý°ú ÁøÇà °úÁ¤¿¡¼­µµ ¸Å¿ì Áß´ëÇÑ ¿ªÇÒÀ» ÇÑ´Ù. µû¶ó¼­ ¿¡½ºÆ®·Î°ÕÀÌ À¯¹æ¾Ï¿¡ ÀÛ¿ëÇÏ´Â ±âÀüÀ» Â÷´ÜÇÏ¿© À¯¹æ¾ÏÀÇ ÁøÇàÀ» ¸·°íÀÚ ÇÏ´Â °ÍÀÌ Ç׾ϳ»ºÐºñ¿ä¹ýÀÇ Ãâ¹ßÀÌ´Ù.
À¯¹æ¾Ï¿¡ ´ëÇÑ ÃÖÃÊÀÇ ³»ºÐºñ¿ä¹ýÀº ¾çÃø ³­¼Ò ÀýÁ¦¼ú·Î 1896³â¿¡ ¿µ±¹ÀÇ ¿Ü°úÀÇ»çÀÎ ºñ½¼(Georage Beatson)ÀÌ Àç¹ßµÈ À¯¹æ¾Ï ȯÀÚ¿¡¼­ ÀÌ ¼ö¼úÀ» ½ÃÇàÇÏ¿© ÁÁÀº Ä¡·á °á°ú¸¦ ÀÔÁõÇÑ ÈÄ ³»ºÐºñ¿ä¹ýÀÇ °³³äÀÇ »ý°åÀ¸¸ç, 1960³â´ë±îÁö´Â ÁÖ·Î ³­¼ÒÀýÁ¦¼ú, ºÎ½Å ÀýÁ¦¼ú, ³úÇϼöü ÀýÁ¦¼ú°ú °°Àº ¼ö¼úÀûÀÎ ¹æ¹ýÀ̳ª ³­¼Ò¿¡ ¹æ»ç¼±À» Á¶»çÇÏ´Â ¹æ¹ý µîÀ» ÅëÇØ ³­¼Ò¿¡¼­ ¿¡½ºÆ®·Î°ÕÀÌ »ý»êµÇ´Â °ÍÀ» Â÷´ÜÇÔÀ¸·Î½á À¯¹æ¾ÏÀ» Ä¡·áÇÏ¿© ±× È¿°ú¸¦ È®ÀÎÇÏ¿´´Ù.(11) 1970³â´ë¿¡ µé¾î¼­¸é¼­ Ç×(ù÷)¿¡½ºÆ®·Î°Õ ¾àÁ¦ÀÎ tamoxifenÀÌ À¯¹æ¾ÏÀÇ Ä¡·á¿¡ »ç¿ëµÇ¸ç, ±× È¿°ú°¡ ÀÎÁ¤µÇ¾î ¼ö¼úÀ» ÀÌ¿ëÇÑ ³­¼ÒÀýÁ¦¼úº¸´Ù´Â ¾à¹°À» ÀÌ¿ëÇÑ Ä¡·á·Î ¹Ù²î°Ô µÇ¾ú´Ù. È£¸£¸ó ¼ö¿ëü ¾ç¼ºÀÎ À¯¹æ¾Ï ȯÀÚ¿¡¼­ »ç¿ëÇÏ´Â tamoxifenÀÌ ÇöÀç±îÁö °¡Àå ´ëÇ¥ÀûÀÎ Ç×(ù÷)¿¡½ºÆ®·Î°Õ ¾àÁ¦ÀÌ´Ù.(3) ÃÖ±Ù¿¡´Â Æó°æ ÈÄ ³­¼ÒÀÇ ±â´ÉÀÌ ÀúÇϵʿ¡ µû¶ó ºÎ½Å¿¡¼­ ºÐºñµÇ´Â ¿¡½ºÆ®·Î°Õ »ý»êÀ» Â÷´ÜÇÒ ¸ñÀûÀ¸·Î ¾Æ·Î¸¶Å¸Á¦ ¾ïÁ¦Á¦ÀÎ letrozole, anastrozole, exmestaneµîÀÌ »ç¿ëµÇ°í ÀÖÀ¸¸ç, Æó°æ Àü ³­¼ÒÀÇ ±â´ÉÀ» ¾ïÁ¦Çϱâ À§ÇØ ¡®È²Ã¼Çü¼º È£¸£¸ó ºÐºñ È£¸£¸ó¡¯ ±æÇ×Á¦ÀÎ goserelinÀ» »ç¿ëÇÏ¿© ¾àÁ¦¿¡ ÀÇÇÑ ³­¼ÒÀýÁ¦ È¿°ú¸¦ º¼ ¼ö ÀÖÀ¸¸ç, ȤÀº ¿¡½ºÆ®·Î°Õ ¼ö¿ëü¸¦ °¨¼Ò½ÃÄÑ ¿¡½ºÆ®·Î°ÕÀÌ È¿°ú¸¦ ¹ßÈÖÇÒ ¼ö ¾øµµ·Ï ÇÏ´Â ¼ö¿ëü Á¦°ÅÁ¦ÀÎ fulvestrantµî ´Ù¾çÇÑ ÀÛ¿ë ±âÀüÀ» °®´Â ¾àÁ¦µéÀÌ À¯¹æ¾ÏÀÇ ³»ºÐºñ¿ä¹ý¿¡ »ç¿ëµÇ°í ÀÖ´Ù.(12,13,14)
À¯¹æ¾ÏÀÇ ³»ºÐºñ¿ä¹ýÀ» À§Çؼ­´Â À¯¹æ¾Ï ¼¼Æ÷°¡ ¿¡½ºÆ®·Î°Õ¿¡ ´ëÇÑ ¼ö¿ëü ´Ü¹éÁúÀ» °¡Áö°í ÀÖ¾î¾ß¸¸ ±× Ä¡·á È¿°ú¸¦ ±â´ëÇÒ ¼ö ÀÖ´Ù. ¼ö¼ú ÈÄ Á¶Á÷ °Ë»ç °á°ú ¶§ È£¸£¸ó ¼ö¿ëü °Ë»ç¸¦ ÇÏ¿© ±× °á°ú È£¸£¸ó ¼ö¿ëü ¾ç¼ºÀ̸é Ç׾Ͽä¹ýÀÌÈÄ ³»ºÐºñ ¿ä¹ýÀ» ½ÃÀÛÇÑ´Ù. ³»ºÐºñ¿ä¹ýÀÇ ÀåÁ¡Àº Ç׾Ͽä¹ý ¶§ º¸ÀÌ´Â ºÎÀÛ¿ëÀÎ Å»¸ð, ±¸Åä ¹× ¼³»ç, ¹éÇ÷±¸ °¨¼ÒÁõ µîÀÇ ½ÉÇÑ ºÎÀÛ¿ëÀÌ ¾ø±â ¶§¹®¿¡ ȯÀÚµéÀÌ Å« ºÒÆí ¾øÀÌ ÁÁÀº »îÀÇ ÁúÀ» À¯ÁöÇÒ ¼ö ÀÖ´Ù. ¶ÇÇÑ °í·ÉÀÇ È¯ÀÚ³ª Àü½Å »óÅ°¡ ÁÁÁö ¾ÊÀº ȯÀÚ¿¡¼­µµ Ç׾Ͽä¹ý´ë½Å¿¡ ¿ì¼± ¼±ÅÃÇÏ¿© »ç¿ëÇϱ⵵ ÇÑ´Ù.(15)
ÇöÀç±îÁö À¯¹æ¾Ï ³»ºÐºñ Ä¡·áÀÇ Ç¥ÁØ ¾àÁ¦·Î »ç¿ëµÇ°í Àִ Ÿ¸ñ½ÃÆæÀÇ Ä¡·á È¿°ú´Â À¯¹æ¾ÏÀÇ Àç¹ßÀ» ¾ïÁ¦Çϰųª À¯¹æ¾Ï ȯÀÚÀÇ »ýÁ¸À» ¿¬ÀåÇÏ´Â Ãø¸é¿¡¼­ ¸Å¿ì È¿°úÀûÀ̸ç, Åõ¿©±â°£Àº Ÿ¸ñ½ÃÆæÀ» 5³â°£ »ç¿ëÇÑ´Ù.(16) ¶ÇÇÑ Æó°æ »óÅ¿¡ µû¶ó ¾Æ·Î¸¶Å¸Á¦ ¾ïÁ¦Á¦ÀÎ letrozole, anastrozole, exmestaneµîÀ» tamoxifenÀ» ´ë½ÅÇÏ¿© Åõ¿©ÇÏ´Â ¹æ¹ý, Åõ¿©ÇÏ´ø tamoxifenÀ» ½ºÀ§Ä¡ÇÏ¿© »ç¿ëÇÏ´Â ¹æ¹ý, tamoxifenÀ» 5³â »ç¿ëÇÑ ÈÄ ¿¬ÀåÇÏ¿© »ç¿ëÇÏ´Â ¹æ¹ýÀÌ ÀÖ´Ù.(12,13,17,18)
tamoxifenÀÇ ÈçÇÑ ºÎÀÛ¿ëÀ¸·Î´Â ¾à°£ÀÇ ¾È¸é È«Á¶, »ý¸® ºÒ¼ø, Áú ºÐºñ¹° µîÀÇ °æ¹ÌÇÑ °ÍµéÀÌ ´ëºÎºÐÀÌÁö¸¸, Àڱ󻸷¾Ï°ú °°Àº Ä¡¸íÀûÀÎ ÇÕº´Áõµµ µå¹°°Ô ¹ß»ýÇϹǷΠtamoxifenÀ» Àå±â°£ º¹¿ëÇϴ ȯÀÚµéÀº ¸Å³â ÀÌ¿¡ ´ëÇÑ Á¤±âÀûÀÎ °ËÁøÀÌ ÇÊ¿äÇÏ´Ù.(19) ¶ÇÇÑ tamoxifenÀº Ç÷Àü ¹× »öÀüÁõÀÇ ºóµµ¸¦ Áõ°¡½ÃÅ°¹Ç·Î ÀÌ¿¡ ´ëÇÑ ÁÖÀÇ°¡ ÇÊ¿äÇÏ´Ù.
 
3. ¹æ»ç¼± Ä¡·á

¹æ»ç¼±Ä¡·á´Â À¯¹æº¸Á¸¼ö¼ú ÈÄ ³²¾ÆÀÖ´Â À¯¹æÁ¶Á÷¿¡¼­ ¾ÏÀÌ Àç¹ßµÇ´Â °ÍÀ» ¸·°Å³ª, À¯¹æÀýÁ¦ ¼ö¼ú ÈÄ °Üµå¶ûÀÌ ¸²ÇÁÀý ÀüÀÌ°¡ ¸¹Àº °æ¿ì¿¡ »ç¿ëµÈ´Ù. ¹æ»ç¼± Ä¡·á´Â °í¿¡³ÊÁöÀÇ ¹æ»ç¼±À» ÀÌ¿ëÇÏ¿© Á¾¾çÀ» Ä¡·áÇÏ´Â °ÍÀ¸·Î ºÐÈ° Á¶»ç¸¦ ÅëÇØ Ä¡·áÇϴµ¥ Á¾¾ç¼¼Æ÷ÀÇ repopulation, reoxygenation, repair, clonogenic cellÀÇ ¼ö, ¹æ»ç¼º ¹Î°¨µµµîÀÌ ¿µÇâÀ» ÁÙ ¼ö ÀÖ´Ù.(20) ¹æ»ç¼± Ä¡·á ÈÄ Á¶Á÷ÀÇ ¼¶À¯È­³ª ±«»ç À§ÇèÀÌ ÀÖ´Â ±³¿øÁ¶Á÷Áúȯ, È«¹Ý¼º³¶Ã¢, ÆóÁúȯÀÌ ÀÖ´Â °æ¿ì ¶Ç °ú°Å¿¡ À¯¹æºÎÀ§¿¡ ¹æ»ç¼± Ä¡·á¸¦ ¹Þ¾Ò´ø ȯÀÚ, ÀÓ½ÅÁßÀΠȯÀÚ´Â ¹æ»ç¼± Ä¡·á¸¦ ¹ÞÀ» ¼ö°¡ ¾ø´Ù.
¹æ»ç¼± Ä¡·á´Â ¼ö¼ú »óó°¡ ³ªÀº ÈÄ ½ÃÀÛÇϴµ¥ ´ë°³ ¼ö¼ú ÈÄ 3~4ÁÖ Áö³ª ÆÈ ¿îµ¿ÀÌ ÀÚÀ¯·Î¿ö Áö°Ô µÇ¸é ½ÃÇàÇÏÁö¸¸ À¯¹æ¾ÏÀÇ Æ¯¼º°ú ȯÀÚÀÇ »óÅ¿¡ µû¶ó ±× ½Ã±â¿Í ¹æ¹ýÀÌ ´Þ¶óÁú ¼ö ÀÖ´Ù. ù° Ç×¾ÏÁ¦ Ä¡·á¸¦ ¸ÕÀú ÇÏ°í ³ªÁß¿¡ ¹æ»ç¼± Ä¡·á¸¦ ÇÏ´Â °æ¿ì, µÑ° Ç×¾ÏÁ¦ Ä¡·á¿Í ¹æ»ç¼± Ä¡·á¸¦ µ¿½Ã¿¡ ÇÏ´Â °æ¿ì, ¼Â° ¹æ»ç¼± Ä¡·á¸¦ ¸ÕÀú ½ÃÇàÇÏ°í ³ªÁß¿¡ Ç×¾ÏÁ¦ Ä¡·á¸¦ ÇÏ´Â °æ¿ì·Î ³ª´­ ¼ö ÀÖ´Ù. ÀÌ ¼¼°¡Áö ¹æ¹ý Áß ¾î´À ¹æ¹ýÀÌ °¡Àå ¿ì¿ùÇÑ È¿°ú°¡ ÀÖ´ÂÁö¿¡ ´ëÇؼ­´Â ÇöÀç Á¤¸³µÇ¾î ÀÖÁö ¾Ê´Ù. ±×·¯³ª Á¾¾ç ÀýÁ¦ ÈÄ º¯¿¬°æ°èºÎ°¡ °¡±õ´Ù°Å³ª ÀÓÆÄÀý ÀüÀÌ°¡ ÀÖ´Â °æ¿ì¿¡´Â ¹æ»ç¼± Ä¡·á¸¦ ¸ÕÀú ½ÃÇàÇÏ°í ³ªÁß¿¡ Ç×¾ÏÁ¦ Ä¡·á¸¦ ÇÏ´Â °ÍÀ» ±ÇÀåÇϱ⵵ ÇÑ´Ù.(21,22)
¹æ»ç¼± Ä¡·á´Â ´ë°³ ¿ù¿äÀϺÎÅÍ ±Ý¿äÀϱîÁö ÀÏÁÖÀÏ¿¡ 5ÀÏ µ¿¾È Ä¡·á¸¦ ÇϹǷÎ, ¹æ»ç¼± Ä¡·á¸¦ ¸¶Ä¡´Âµ¥ ´ë°³ 6ÁÖ¿¡¼­ 7ÁÖÁ¤µµ°¡ ÇÊ¿äÇÏ´Ù.
¹æ»ç¼± Ä¡·á´Â ¾ÈÀüÇÑ Ä¡·á¹ýÀ¸·Î ¹æ»ç¼±À» Á¶»çÇÏ´Â ¾ç°ú Ƚ¼ö¸¦ Á¶ÀýÇÏ¿© ºÎÀÛ¿ëÀ» ÁÙÀÏ ¼ö ÀÖ´Ù. ºÎÀÛ¿ëÀ¸·Î´Â ¹æ»ç¼±À» Á¶»ç ¹ÞÀº ÇǺΰ¡ È­»óÀ» ÀÔ´Â °Íó·³ º¯Çϰųª, °Ë°Ô Âø»öµÇ´Â ÇüŸ¦ º¸À̱⵵ Çϸç, ÅëÁõÀ» ´À³¢´Â °æ¿ì°¡ °¡Àå ÈçÇÏ´Ù. ÀÌ·¯ÇÑ º¯È­´Â ÀϹÝÀûÀ¸·Î Ä¡·á°¡ ³¡³ª¸é ´ëºÎºÐ È£ÀüµÇÁö¸¸ ÇǺΰ¡ µÎ²®°í µüµüÇÑ ´À³¦Àº ¿À·§µ¿¾È Áö¼ÓµÇ±âµµ ÇÑ´Ù. ¶Ç À¯¹æ¿¡ ¹æ»ç¼±À» Á¶»çÇÏ¸é ±× ¹ØÀÇ Æó¿¡µµ ¿µÇâÀ» ¹ÌÃÄ ¸¶¸¥ ±âħ, ¹Ì¿­ µîÀÌ ³ªÅ¸³ª´Â ¹æ»ç¼± Æó·ÅÀÌ »ý±æ ¼ö ÀÖÀ¸³ª µå¹® ÀÏÀÌ¸ç ½Ã°£ÀÌ Áö³ª¸é Á¤»óÀ¸·Î µ¹¾Æ¿Â´Ù.

Âü°í¹®Çå
1. Demicheli R, Terenziani M, Valagussa P, Moliterni A, Zambetti M, Bonadonna G. Local recurrences following mastectomy: support for the concept of tumor dormancy. J Natl Cancer Inst 1994;86:45-8.
2. Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002;347:1233-41.
3. Early Breast Cancer Trialists¡¯s Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet 1998;352(9132):930-942.
4. Lohrisch C, Paltiel C, Gelmon K, et al. Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol 2006;24:4888-94.
5. Wood WC, Budman DR, Korzun AH, Cooper MR, Younger J, Hart RD, et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 1994;330:1253-59.
6. Bang SM, Heo DS, Lee KH, Byun JH, Chang HM, Noh DY, et al. Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma. Cancer 2000;89:2521-6.
7. Piccart MJ, Di Leo A, Beauduin M, Vindevoghel A, Michel J, Focan C, et al. Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. J Clin Oncol 2001;19:3103-10.
8. Mamounas EP, Bryant J, Lembersky B, Fehrenbacher L, Sedlacek SM, Fisher B, et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 2005;23:3686-96.
9. Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005;352:2302-13.
10. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsh A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72.
11. Gradishar WJ, Jordan VC: Endocrine therapy of breast cancer, in Bland KI, Copeland EM III (eds): The Breast: Comprehensive Management of Benign Malignant Disease. Philadelphia: WB Saunders, 1998, p 1350.
12. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, et al. ATAC Trialists¡¯ Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet 2002;359:2131-9.
13. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Howell A et al. The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists¡¯ Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003;98:1802-10.
14. Early Breast Cancer Trialists¡¯ Collaborative Group. Ovarian ablation in early breast cancer: overview of the randomized trials. Lancet 1996;348:1189-96.
15. Cummings FJ, Gray R, Tormey DC, et al. Adjuvant tamoxifen versus placebo in elderly women with node positive breast cancer: long-term follow-up and cause of death. J Clin Oncol 1993;11(1):29-35.
16. Stewart HJ, Forrest AP, Everington D, et al. Randomized comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group. Br J Cancer 1996;74(2):297-299.
17. Boccardo F, Rubagotti A, Puntoni M, Guglielmini P, Amoroso D, Fini A, et al. Switching to anastrozole versus continued tamoxifen of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol 2005;23:5138-47.
18. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005;97:262-71.
19. Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham L, Wolmark N, et al. Five Versus More Than Five Years of Tamoxifen Therapy for Breast Cancer Patients With Negative Lymph Nodes and Estrogen Receptor-Positive Tumors JNCI J Natl Cancer Inst (1996) 88(21): 1529-1542.
20. Steel GG. Cell survival as a determinant of tumour response. In: Steel GG, editor. Basic clinical radiobiology. London: Arnold; 2002. p. 52-63.
21. Toledano A, Azria D, Garaud P, et al. Phase III trial of concurrent or sequential adjuvant chemotherapy after conservative surgery for early-stage breast cancer: final results of the ARCOSEIN trial. J Clin Oncol 2007;25:405-10.
22. Balduzzi A, Leonardi M, Cardillo A, Orecchia R, Dellapasqua S, Iorfida M, et al. Timing of adjuvant systemic therapy and radiotherapy after breast-conserving surgery and mastectomy. Cancer Treat Rev 2010;36(6):443-450.
22. Balduzzi A, Leonardi M, Cardillo A, Orecchia R, Dellapasqua S, Iorfida M, et al. Timing of adjuvant systemic therapy and radiotherapy after breast-conserving surgery and mastectomy. Cancer Treat Rev 2010;36(6):443-450.

[ ÇÏÁ¤È¯ ±âÀÚ news@medicalilbo.com ]
ÇÏÁ¤È¯ ±âÀÚ ±âÀÚÀÇ ´Ù¸¥ ±â»ç º¸±â
±â»çÁ¦º¸ ¹× º¸µµÀÚ·á news@medicalilbo.com
¢Æ¢Æ ÀÇ·áÀϺ¸ ¢Æ¢Æ(www.medicalilbo.com) - copyright ¨Ï ¢Æ¢Æ ÀÇ·áÀϺ¸ ¢Æ¢Æ. ¹«´ÜÀüÀç & Àç¹èÆ÷ ±ÝÁö
´ñ±Û´Þ±â
  • ¸¹À̺»±â»ç
  • È­Á¦ÀÇ ´º½º

樨毢

È­Á¦ÀÇ µ¿¿µ»ó
  • ȸ»ç¼Ò°³
  • ±¤°í¾È³»
  • Á¦ÈÞ·±¤°í¹®ÀÇ
  • ±â»çÁ¦º¸
  • Á¤±â±¸µ¶½Åû
  • °í°´¼¾ÅÍ
  • ÀúÀÛ±ÇÁ¤Ã¥
  • ȸ¿ø¾à°ü
  • °³ÀÎÁ¤º¸Ãë±Þ¹æħ
  • À̸ÞÀÏÁÖ¼Ò¹«´Ü¼öÁý°ÅºÎ
  • RSS
  • ÀÇ·áÀϺ¸ www.medicalilbo.com | ¼³¸³ÀÏ : 2009³â 9¿ù 7ÀÏ | ¥Ø 06653 ¼­¿ï½Ã ¼­Ãʱ¸ ¼­Ãʵ¿ 1589-14 ½Å¼º¿ÀÇǽºÅÚ Bµ¿ 407È£
    »ç¾÷ÀÚµî·Ï¹øÈ£ : 105-07-38362 | µî·Ï¹øÈ£ : ¼­¿ï½Ã ´Ù 09845
    ÀüÈ­ : 02) 333-3739, 363-3730 ±¤°í¹®ÀÇ : 02) 333-3739 | Æѽº 02) 363-3730 |  news@medicalilbo.com
    Copyright ¨Ï 2009 medicalilbo.com All right reserved.
    ¢Æ¢Æ ÀÇ·áÀϺ¸ ¢Æ¢ÆÀÇ ¸ðµç ÄÜÅÙÃ÷(±â»ç)´Â ÀúÀ۱ǹýÀÇ º¸È£¸¦ ¹Þ½À´Ï´Ù. ¹«´Ü ÀüÀç·º¹»ç·¹èÆ÷ µîÀ» ±ÝÇÕ´Ï´Ù.